Sequential and combination treatments with novel agents in chronic lymphocytic leukemia
Chemoimmunotherapy has been the standard of care for patients with chronic lymphocytic leukemia for a long time. However, over the last few years, novel agents have produced unprecedented outcomes in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia. With the advent of these targe...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2019-11-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/9117 |